Benjamin Edwards Inc. Has $3.27 Million Holdings in Pfizer Inc. (NYSE:PFE)

Benjamin Edwards Inc. cut its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 48.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 123,269 shares of the biopharmaceutical company's stock after selling 116,989 shares during the quarter. Benjamin Edwards Inc.'s holdings in Pfizer were worth $3,270,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Retirement Wealth Solutions LLC bought a new position in Pfizer during the 4th quarter valued at $26,000. Rialto Wealth Management LLC acquired a new position in Pfizer in the fourth quarter worth about $26,000. Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer in the fourth quarter valued at about $28,000. Noble Wealth Management PBC bought a new position in Pfizer during the 4th quarter worth approximately $31,000. Finally, Curio Wealth LLC bought a new stake in shares of Pfizer in the 4th quarter valued at approximately $32,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Citigroup restated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. UBS Group raised their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Finally, Cantor Fitzgerald began coverage on Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $29.17.

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the business's stock in a transaction dated Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.06% of the stock is owned by insiders.

Pfizer Price Performance

PFE traded down $0.10 during trading on Wednesday, reaching $22.78. The stock had a trading volume of 48,160,808 shares, compared to its average volume of 40,426,421. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The firm has a market capitalization of $129.18 billion, a price-to-earnings ratio of 16.15, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. The stock has a 50 day moving average of $24.15 and a two-hundred day moving average of $25.65. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter last year, the business posted $0.82 earnings per share. The company's quarterly revenue was down 7.8% on a year-over-year basis. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.55%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's payout ratio is 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.